Daily non-political popular news in brief.
Safety analyses of clinical data for bifeprunox in patients with schizophrenia
03-30-2007 · EurekAlert!Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth (NYSE:WYE), and Lundbeck A/S presented clinical study results on bifeprunox at an international medical congress this week. Safety analyses suggest bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, was associated with a favorable weight and lipid profile, comparable with placebo. In addition, increases in weight occurred in patients receiving active references versus placebo.
Read more »
Keywords: safety, analyses, clinical, data, bifeprunox, patients, schizophrenia, analyse, patient
« Previous | Next »
Similar news on "Safety analyses of clinical data for bifeprunox in patients with schizophrenia":
- New long-term data analyses for Bifeprunox show favorable effects vs. placebo
05-22-2007 · EurekAlert!
Solvay Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division of Wyeth, and Lundbeck A/S presented clinical study results on bifeprunox, an investigational treatment for adult patients diagnosed with schizophrenia, today at the 2007 annual meeting of the American Psychiatric Association. New analyses of six-month data in stabilized adult patients with schizophrenia from a double-blind, placebo-controlled study demonstrated that bifeprunox maintained stability vs. placebo and displayed a favorable weight and lipid profile comparable with placebo.
Similar news · Read more »
- Violence in schizophrenia patients more likely among those with childhood conduct problems
07-02-2007 · EurekAlert!
Some people with schizophrenia who become violent may do so for reasons unrelated to their current illness, according to a new study analyzing data from the Clinical Antipsychotic Trials for Intervention Effectiveness.
Similar news · Read more »
- Clinical trials nebulized formoterol fumarate: Long-term and cardiovascular safety COPD
10-24-2007 · EurekAlert!
Data from two Phase III clinical trials were presented today in Chicago at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians, supporting the use of Perforomist Inhalation Solution as a safe and effective maintenance treatment for COPD patients.
Similar news · Read more »
- New Analyses of long-term LIALDA (mesalamine) data presented at ACG
10-15-2007 · EurekAlert!
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis. These analyses of LIALDA's 303 trial, a long-term, Phase III, open-label 12-14 month extension study, are being presented this week at the American College of Gastroenterology meeting in Philadelphia.
Similar news · Read more »
- Drug-eluting and bare-metal stents equal in risk of blood clots, heart attacks and death
03-24-2007 · EurekAlert!
Although the use of stents to treat coronary artery disease has soared during the past decade thanks to novel equipment and new implant techniques, clinical data has recently raised concerns around the safety of drug-eluting stents (DES) and their risk of post-procedure complications. A study presented today at the American College of Cardiology’s Innovation in Intervention: i2 Summit compared rates of complications in thousands of patients who received bare-metal stents (BMS) or DES.
Similar news · Read more »
- Clinical trial data for Perforomist Inhalation Solution to be presented at ATS on May 20, 2007
05-16-2007 · EurekAlert!
Clinical trial data for Perforomist Inhalation Solution will be presented at ATS on May 20, 2007. Data from Phase III pivotal trial demonstrates safety and efficacy of first FDA-approved nebulized formoterol fumarate for patients with moderate to severe COPD.
Similar news · Read more »
- Clinical trial data for Perforomist Inhalation Solution presented at International ATS Conference
05-21-2007 · EurekAlert!
New product recently approved by FDA for long-term maintenance treatment of COPD bronchoconstriction; data demonstrate first nebulized formoterol fumarate provides improved lung function comparable to dry powder formoterol, enhanced patient quality of life, and positive safety profile.
Similar news · Read more »
- EVEREST data on use of tolvaptan published in JAMA and featured at ACC
03-27-2007 · EurekAlert!
Once-daily dosing with Otsuka's investigational oral medication tolvaptan, a vasopressin receptor antagonist, was associated with improvements in signs and symptoms of acutely decompensated heart failure in hospitalized patients receiving conventional care, without an adverse effect on their long-term survival versus placebo. These data are from the short- and long-term analyses of the international landmark trial EVEREST published in the March 28 issue of JAMA and presented at ACC.
Similar news · Read more »
- Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients
10-05-2007 · EurekAlert!
Urologists at Thomas Jefferson University Hospital are studying whether a neo-bladder construct grown from a patient's own cells can improve bladder function for adult spinal cord injury patients. Jefferson is only one of six sites in the US enrolling participants in this clinical trial for the lab-grown neo-bladder construct that will involve a total of 10 patients.
Similar news · Read more »
- MERLIN TIMI-36 study provides new safety & efficacy data for unique anti-anginal therapy
03-27-2007 · EurekAlert!
Chest pain due to a shortage of blood in the heart, known as angina, is a condition that affects millions of Americans. The most recently approved new pharmaceutical approach to treat chronic angina is a novel drug called ranolazine, which was approved in 2006 for use as second line therapy in patients who continue to experience angina despite treatment with another class of anti-anginal medication.
Similar news · Read more »
